Ultrasound therapy developer Theraclion has opened an office in Hong Kong, the People's Republic of China, which will serve as the company's Asia branch.
The greatest number of procedures for breast fibroadenomas and thyroid nodules takes place in Asia, and in China alone, 1.2 million patients are diagnosed with fibroadenomas each year -- making Asia a key focus region for the company, Theraclion said.
In addition to the new Asia office, Theraclion has appointed Giuliano Laghi as its new business development director for Italy and Southern Europe. Laghi joined Theraclion earlier this year as vice president for the regions and has previously served at Johnson & Johnson and the Italian diagnostic ultrasound division of Toshiba Medical Systems.
Finally, Theraclion has also hired sales agents in Switzerland and Finland to strengthen its presence across Europe.
